COHANCE Q2 FY27 Results & Earnings Analysis
Sentiment: Neutral (Confidence: medium)
Earnings Summary
Cohance Lifesciences reported Q2 FY27 revenue of INR4,767 million, up 13% QoQ, with adjusted EBITDA margin improving to 10% sequentially. YoY performance remained lower due to reduced Pharma CDMO and AgChem contribution and unfavorable mix. Management expects H2 FY27 to deliver YoY growth on revenue and EBITDA, driven by small molecule deliveries, API+ resilience, Sapala growth, and NJ Bio approaching breakeven. Key risks include Suryapet facility closure and USFDA classifications.
Management Tone
- Prepared Remarks: Good — Management emphasized sequential recovery (revenue +13% QoQ, adjusted EBITDA margin improving to 10%) and expected improvement in H2 with better order visibility, although YoY performance remained lower.
- Q&A Session: Neutral — Analysts pressed on key uncertainties including Suryapet facility closure and cost savings; management provided limited quantification and referred to ongoing assessment, while expressing confidence on H2 improvement.
Revenue Growth Drivers
- Pharma CDMO sequential recovery led by small molecules and improved order/reload visibility
- Sapala strong momentum in nucleic acids (oligo)
- New commercial programs (small molecule RSM) from large pharma, incremental to H2 guidance
Growth vs Margin Focus
Management emphasized not just higher revenues but improving quality of revenues, mix, and utilization to support operating leverage, while also expecting H2 YoY growth.
About Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited)
Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) (COHANCE) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.